Canterbury DHB

Context

Relapsed or Refractory Patients

No precise guidelines can be given here. The decision for or against further treatment and its intensity will depend on several factors including:

The patient's wishes must be taken into consideration. The choice of treatment will depend upon the aims of any therapy being considered, whether palliative or intensive.

For an individual perspective on this topic, see:

High dose methylprednisolone

Methylprednisolone (1 g/m2/day IV for 5 days), either alone or in combination with rituximab is an effective salvage regimen in patients who are refractory to fludarabine, have p53 abnormalities and/or have adverse cytogenetics. Infectious complications have been reported frequently including pneumonia, gram-negative septicaemia, pneumocystis and herpes viruses.

For further information on regimen and outcomes see:

Ibrutinib

About this Canterbury DHB document (5515):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

September 2018

Next Review:

September 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5515